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Monocytes, which are derived from monoblasts, haematopoietic stem cell precursors in the bone marrow (BM), circulate in the bloodstream before extravasating into tissues of the body. In the tissues, monocytes differentiate into various types of tissue resident macrophages depending on their anatomical locations, for example Langerhans cells in skin, Kupffer cells in liver, osteoclasts in bone, microglia in central nervous system, alveolar macrophages in lung and synovial type A cells in synovial joint [1-5] (Fig. 1). Monocytes/macrophages can perform phagocytosis by using mediators such as antibodies or complement components that coat the microbes or by binding to the pathogens directly via specific receptors that recognize them (endocytosis). Additionally, monocytes/macrophages are able to kill infected host cells, through an immune system response, termed antibodymediated cellular cytotoxicity [4, 6]. Moreover, they are unique immunoregulatory cells able to both stimulate and suppress immune activities, including antigen presentation to T cells and controlled secretion of a wide range of cytokines and growth factors
. The bottom line in monocyte/macrophage function is that they play a major role in the inborn defence system by way of killing pathogens through phagocytosis and cellular cytotoxicity, and immunomodulation [1, 7] . [1, 3, 11, 12] (Fig. 1) .
Role of monocytes in neovascularization Like neutrophils, one interesting function of monocytes/ macrophages is to promote angiogenesis related to inflammatory reactions [8-10]. Angiogenesis (or neovascularization) is a major element of inflammatory processes including subsequent repair cascades [4]. During the early inflammatory process, circulating blood monocytes extravasate into tissues [1]. Initially, neighbouring endothelial and inflammatory cells regulate this monocyte passage through vessel walls by releasing of a series of adhesion and chemotactic materials [1, 2, 11]. Along chemotactic and oxygen gradients between normal and injured tissues, extravasated monocytes move and gather into hypoxic and/or necrotic cores of diseased tissues before differentiation into tissue macrophages. The representative pathological tissues to which monocytes/ macrophages are apt to accumulate are as follows: solid tumours, myocardial or cerebral infarction, synovial joints of chronic arthritis or atheromatous plaques, bacterial infection and healing wounds
After differentiation from monocytes, macrophages in tissue have been known to exist as polarized populations, M1 and M2 subsets [12] [13] [14] 
Monocytes from umbilical cord blood
Monocytes constitute ~5-10% of peripheral blood leucocytes in human beings [77, 78], whereas these cells comprise 2% of BM mononuclear cells [78]. By contrast, no difference in monocyte content between UCB and adult peripheral blood has been reported [79, 80]. Therefore, BM and UCB, as well as peripheral blood can be potential candidates as a source of autologous or allogeneic monocytes/macrophages. In fact, BM and UCB are the current gold standard sources of haematopoietic progenitor cells used to reconstitute blood lineages after myeloablative therapy in malignant and non-malignant blood disease. However, the potential of their stem cell population for cell-based therapy has also been demonstrated in other degenerative disorders, especially ischemic disease. There is accumulating evidence that delivery of BM-or UCB-derived stem or mononuclear cells to areas of ischemia by direct local transplantation or injection into blood, can improve the pathological lesion and functional impairment in pre-clinical [81-87] and clinical studies [88-92]. This improvement has been thought to result in part from paracrine effect with an increase in angiogenesis induced by stem cells in the ischemic and/or peri-ischemic core [82, 85, 93-95] even though the mechanisms to exert their angiogenic effects are not completely understood. Recently, our group revealed that surgical intramyocardial multiple one-time injections of autologous BM mononuclear cells in patients with refractory angina showed a progressive improvement in angina classification as well as in reperfused myocardium area during 18 month follow-up [96]. It is of interest that a positive correlation was noted between monocyte concentration in the graft formulation and clinical improvement (Table 2). This suggests that monocytes should play a major role in functional recovery, probably through induction of myocardial angiogenesis. Meanwhile, monocytes in UCB essentially are unique compared to those originating in adult BM and peripheral blood [84]. Only adult monocytes are activated by hepatocyte growth factor, which is essential for normal monocyte functions such as antigen presentation [97]. The UCB monocytes express less HLA-DR than adult cells so their cytotoxic capacity is lower [98]. Furthermore, UCB monocytes do not differentiate into mature dendritic cells to the same extent as mature monocytes even with stimulation by IL-4 and GM-CSF [99]; dendritic cells play a major role in activation of naïve T cells. Secretory function is also different between UCB monocytes and adult blood monocytes. Less secretion of IL-1␤ and TNF-␣, both of which stimulate inflammation as well as play a major role in immune reactions such as GvHD [100], from UCB monocytes after exposure to recombinant interferon-␥ is most likely related to differences in the expression
